- Dr. Reddy's Asked To Submit Revised Protocol For Sputnik V Vaccine Trials
- Sputnik V Vaccine 92 per cent 'Effective' Against Coronavirus, Claims Russia
- First Batch Of Russia's Sputnik V Vaccine To Arrive In Kanpur For Phase 2, 3 Trials
- India and China Can Produce Russia's Sputnik V Vaccine: Vladimir Putin
The price per dose of the Russian Covid-19 vaccine Sputnik V is going to be much lower than that of the vaccines of US drug giants Pfizer and Moderna, the Russian vaccine’s official Twitter account confirmed.
The official account said, "Translating pharma lingo: the announced price of Pfizer of USD 19.50 and Moderna of USD 25-USD 37 per dose actually means their price of USD 39 and USD 50-USD 74 per person. Two doses are required per person for the Pfizer, Sputnik V and Moderna vaccines. The price of Sputnik V will be much lower.”
Russia became the first country to register the world’s first Covid-19 vaccine on August 11. The vaccine – Sputnik was developed by the Gamaleya National Research Centre for Epidemiology and Microbiology of the Russian Healthcare Ministry.
On November 11, Russia confirmed that its vaccine Sputnik V is 92 per cent effective at protecting people from coronavirus.
On November 17, Moderna, in its official statement, had announced that the independent, U.S. NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273 has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5 per cent.
For in-depth, objective and more importantly balanced journalism, Click here to subscribe to Outlook Magazine